Spexis Granted Extension for 2023 Annual Report Amid Dispute with SPRIM

Spexis AG, a clinical-stage biopharmaceutical firm focused on macrocycle therapeutics for rare diseases and oncology, has been given a second extension by SIX Exchange Regulation AG for publishing its 2023 annual report. The new deadline is July 31, 2024. This decision follows ongoing legal and financial issues involving Spexis' major creditor, SPRIM Global Investments.

The extension allows Spexis to address enforcement actions by SPRIM, which the company alleges are wrongful. Simultaneously, the company released its unaudited financial statements, showing a net loss of 19.6 million CHF for 2023, and reduced equity from 19.4 million CHF in 2022 to 2.3 million CHF.

Spexis remains in provisional moratorium until August 8, 2024. The company is negotiating with SPRIM for a potential debt restructuring, which could prevent liquidation. Nonetheless, the future remains uncertain pending these discussions.